Sangamo Therapeutics Reports Business Highlights and Second Quarter 2020 Financial Results

dnrt8765

Conference Call and Webcast Scheduled for 5:00 p.m. Eastern Time

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today reported second quarter 2020 financial results and recent business highlights.

“We are very excited about our global collaboration agreement announced with Novartis last week. This is our second impactful partnership announced this year, and we believe it affirms the value our industry sees in our zinc finger technology,” said Sandy Macrae, CEO of Sangamo. “By advancing our robust partnership strategy, we proactively expand our genomic medicines pipeline into potential additional new indications, create substantial value for shareholders, and advance our

Mersana Therapeutics Announces Second Quarter 2020 Financial Results and Provides Business Update

dnrt8765

 – Presented positive interim expansion cohort data from XMT-1536 Phase 1 study at ASCO demonstrating a 35% objective response rate, including 10% complete response rate and 80% disease control rate in ovarian cancer

– Initiated patient dosing in a Phase 1 dose escalation study of XMT-1592, a NaPi2b-targeted Dolasynthen ADC

– Raised $240 million in gross proceeds from ATM and public offering; projected to fund current operating plan commitments for more than two years

CAMBRIDGE, Mass., Aug. 07, 2020 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of

Denali Therapeutics Reports Second Quarter 2020 Financial Results and Business Highlights

dnrt8765

SOUTH SAN FRANCISCO, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) — Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (“BBB”) for neurodegenerative diseases, today reported financial results for the second quarter ended June 30, 2020 and provided business highlights.

“We are thrilled with the strong progress across our pipeline, the continued productivity across the company despite the current situation imposed by the COVID-19 pandemic, and a new collaboration with Biogen on our LRRK2 program for Parkinson’s disease patients and certain TV-enabled programs,” said Ryan Watts, Ph.D., CEO. “I

Scholar Rock Reports Second Quarter 2020 Financial Results and Highlights Business Progress

dnrt8765

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors play a fundamental role, today reported financial results for the second quarter ended June 30, 2020 and highlighted recent progress and upcoming milestones for its pipeline programs.

“I am impressed by the execution of the team, and momentum is rapidly building for our lead clinical programs, SRK-015 in SMA and SRK-181 in immuno-oncology, towards several potential value-creation opportunities in late 2020 and throughout 2021,” said Tony Kingsley, President and CEO of Scholar Rock. “Scholar Rock has